Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Markers of Response in a Phase II Trial of Axitinib in Advanced Melanoma

NCT01533948 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT01533948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01533948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Markers of Response in a Phase II Trial of Axitinib in Advanced Melanoma
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2012
Completion date
July 31, 2015
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extraocular extension melanoma, metastatic intraocular melanoma, recurrent intraocular melanoma, recurrent melanoma, stage iiia intraocular melanoma, stage iiia melanoma, stage iiib intraocular melanoma, stage iiib melanoma, stage iiic intraocular melanoma, stage iiic melanoma, stage iv intraocular melanoma, stage iv melanoma